Research progress on influencing factors of drug resistance of carbapenem-resistant <i>Klebsiella pneumoniae</i>_West China Medical Journal

Authors：

TAN Shengtong ¹ , ZHANG Xinping ² ,  CHEN Xiuwen ²

1. School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang 330006, P. R. China;
2. Department of Nosocomial Infection Control, Jiangxi Children’s Hospital, Nanchang 330066, P. R. China;

Corresponding?author：

CHEN Xiuwen, Email: wen8023@126.com

Keywords：

Carbapenem-resistant Klebsiella pneumoniae; resistance mechanism; drug resistance; influencing factor

DOI：

10.7507/1002-0179.202302148

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In recent years, with the wide application of carbapenems, the resistance of Enterobacterium to carbapenems has become increasingly high, leading to a large number of carbapenem-resistant Klebsiella pneumoniae (CRKP). These bacteria are often resistant to many different types of antibacterial drugs, including carbapenems, which leads to clinical treatment failure and seriously threatens the life safety of patients. Currently, these bacteria have become an independent risk factor for patients’ death. This article reviews the drug resistance, infection status and influencing factors, and medication therapy of CRKP, in order to facilitate the clinical diagnosis, treatment, and disease process control of CRKP infection, and provide reference for curbing bacterial drug resistance.

Citation： TAN Shengtong, ZHANG Xinping, CHEN Xiuwen. Research progress on influencing factors of drug resistance of carbapenem-resistant Klebsiella pneumoniae. West China Medical Journal, 2023, 38(3): 459-464. doi: 10.7507/1002-0179.202302148 Copy

1.	Soares de Moraes L, Gomes Magalhaes GL, Material Soncini JG, et al. High mortality from carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Microb Pathog, 2022, 167: 105519.
2.	康蓓佩, 付曉蕊, 賀文芳, 等. 耐碳青霉烯類的肺炎克雷伯菌的感染特點及耐藥基因分析. 國際檢驗醫學雜志, 2019, 40(24): 2991-2994, 2998.
3.	楊沙沙, 王喜仁, 韓杰, 等. 美國 CLSI 抗菌藥物敏感試驗操作標準(2010 年版)部分變更內容. 中國感染控制雜志, 2010, 9(4): 303-304.
4.	Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis, 2017, 215(Suppl_1): S28-S36.
5.	Oteo J, Pérez-Vázquez M, Bautista V, et al. The spread of KPC-producing Enterobacteriaceae in Spain: WGS analysis of the emerging high-risk clones of Klebsiella pneumoniae ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. J Antimicrob Chemother, 2016, 71(12): 3392-3399.
6.	Liao W, Liu Y, Zhang W. Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: a review over the last 10 years. J Glob Antimicrob Resist, 2020, 23: 174-180.
7.	Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol, 2013, 4: 48.
8.	禹明均, 鄭小鵬, 李春江. 耐碳青霉烯類肺炎克雷伯菌耐藥機制的研究進展. 現代鹽化工, 2022, 49(3): 13-15.
9.	許曉娜, 王志盛, 張小倩, 等. 耐碳青霉烯類肺炎克雷伯菌耐藥機制的研究進展. 河南醫學研究, 2018, 27(17): 3125-3126.
10.	Ho PL, Cheung YY, Wang Y, et al. Characterization of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from a healthcare region in Hong Kong. Eur J Clin Microbiol Infect Dis, 2016, 35(3): 379-385.
11.	王芬芳, 楊坤祥, 徐華. 新生兒醫院感染肺炎克雷伯菌的耐藥性分析. 國際檢驗醫學雜志, 2017, 38(1): 107-109.
12.	趙容陶, 娜木罕, 朝寶, 等. 新生兒肺炎克雷伯菌敗血癥的臨床特征及耐藥性分析. 中國婦幼健康研究, 2022, 33(6): 96-102.
13.	杜逸亭, 胡旭紅, 楊曉榮, 等. 新生兒肺炎克雷伯菌敗血癥臨床特點和藥敏分析. 四川醫學, 2017, 38(12): 1420-1423.
14.	2020 年全國細菌耐藥監測報告. 中國合理用藥探索, 2022, 19(11): 83.
15.	郝東俠, 王彥宏, 王旭東. 醫院獲得性耐碳青霉烯肺炎克雷伯桿菌感染的特點、危險因素分析及預后. 中國臨床醫生雜志, 2019, 47(5): 522-525.
16.	Pellegrini JL, Aguirre C, Soto SM, et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from a pediatric hospital from Corrientes, Argentina. Rev Chilena Infectol, 2022, 39(2): 109-116.
17.	Candevir Ulu A, Güven G?kmen T, Kibar F, et al. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae at a Turkish centre: is the increase of resistance a threat for Europe?. J Glob Antimicrob Resist, 2017, 11: 10-16.
18.	Ghamari M, Beigverdi R, Jabalameli F, et al. Antimicrobial resistance pattern, virulence determinants and molecular analysis of carbapenem-resistant Klebsiella pneumoniae isolated from clinical samples in Iran. FEMS Microbiol Lett, 2022, 369(1): fnac100.
19.	Chen IR, Huang PH, Wu PF, et al. Clinical characteristics and outcomes of 56 patients with pneumonia caused by carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist, 2021, 25: 326-330.
20.	Lee YL, Ko WC, Hsueh PR. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents, 2022, 60(5/6): 106679.
21.	Tesfa T, Mitiku H, Edae M, et al. Prevalence and incidence of carbapenem-resistant K. pneumoniae colonization: systematic review and meta-analysis. Syst Rev, 2022, 11(1): 240.
22.	Ahmed El-Domany R, El-Banna T, Sonbol F, et al. Co-existence of NDM-1 and OXA-48 genes in carbapenem resistant Klebsiella pneumoniae clinical isolates in Kafrelsheikh, Egypt. Afr Health Sci, 2021, 21(2): 489-496.
23.	Thapa S, Adhikari N, Shah AK, et al. Detection of NDM-1 and VIM genes in carbapenem-resistant Klebsiella pneumoniae isolates from a tertiary health-care center in Kathmandu, Nepal. Chemotherapy, 2021, 66(5/6): 199-209.
24.	Berglund B, Hoang NTB, Lundberg L, et al. Clonal spread of carbapenem-resistant Klebsiella pneumoniae among patients at admission and discharge at a Vietnamese neonatal intensive care unit. Antimicrob Resist Infect Control, 2021, 10(1): 162.
25.	Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis, 2014, 20(7): 1170-1175.
26.	Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob, 2017, 16(1): 18.
27.	Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev, 2016, 80(3): 629-661.
28.	Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol, 2018, 8: 4.
29.	Gomez-Simmonds A, Uhlemann AC. Clinical implications of genomic adaptation and evolution of carbapenem-resistant Klebsiella pneumoniae. J Infect Dis, 2017, 215(Suppl_1): S18-S27.
30.	Arato V, Raso MM, Gasperini G, et al. Prophylaxis and treatment against Klebsiella pneumoniae: current insights on this emerging anti-microbial resistant global threat. Int J Mol Sci, 2021, 22(8): 4042.
31.	Han R, Niu M, Liu S, et al. The effect of siderophore virulence genes entB and ybtS on the virulence of carbapenem-resistant Klebsiella pneumoniae. Microb Pathog, 2022, 171: 105746.
32.	于新橋. 早產兒敗血癥臨床治療中碳青霉烯類和 β-內酰胺類藥物的使用與耐藥性分析. 檢驗醫學與臨床, 2017, 14(7): 1021-1024.
33.	Ruiz J, Gordon M, Villarreal E, et al. Influence of antibiotic pressure on multi-drug resistant Klebsiella pneumoniae colonisation in critically ill patients. Antimicrob Resist Infect Control, 2019, 8: 38.
34.	Li M, Yang S, Yao H, et al. Retrospective analysis of epidemiology, risk factors, and outcomes of health care-acquired carbapenem-resistant Klebsiella pneumoniae bacteremia in a Chinese tertiary hospital, 2010-2019. Infect Dis Ther, 2023, 12(2): 473-485.
35.	Qian Y, Bi Y, Liu S, et al. Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review. Ann Palliat Med, 2021, 10(7): 7340-7350.
36.	Liu P, Li X, Luo M, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis. Microb Drug Resist, 2018, 24(2): 190-198.
37.	Yuan Y, Wang J, Yao Z, et al. Risk Factors for carbapenem-Resistant Klebsiella pneumoniae bloodstream infections and outcomes. Infect Drug Resist, 2020, 13: 207-215.
38.	Lu J, Zhang A, Han L, et al. Clinical outcomes and risk factors for death following carbapenem-resistant Klebsiella pneumoniae infection in solid organ transplant recipients. Microbiol Spectr, 2023, 11(1): e0475522.
39.	Manandhar S, Amatya P, Ansari I, et al. Risk factors for the development of neonatal sepsis in a neonatal intensive care unit of a tertiary care hospital of Nepal. BMC Infect Dis, 2021, 21(1): 546.
40.	Akgul F, Bozkurt I, Sunbul M, et al. Risk factors and mortality in the carbapenem-resistant Klebsiella pneumoniae infection: case control study. Pathog Glob Health, 2016, 110(7/8): 321-325.
41.	Qin X, Wu S, Hao M, et al. The colonization of carbapenem-resistant Klebsiella pneumoniae: epidemiology, resistance mechanisms, and risk factors in patients admitted to intensive care units in China. J Infect Dis, 2020, 221(Suppl 2): S206-S214.
42.	Ding Y, Wang Y, Hsia Y, et al. Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. Ann Clin Microbiol Antimicrob, 2019, 18(1): 36.
43.	陳虹宇, 黃雙雙, 孫麗芳, 等. 兒童檢出耐碳青霉烯類肺炎克雷伯菌的影響因素分析. 檢驗醫學與臨床, 2021, 18(2): 168-171.
44.	方清永, 李迎麗, 邱景富. ICU 耐碳青霉烯類肺炎克雷伯菌醫院獲得性肺炎危險因素分析. 國際檢驗醫學雜志, 2017, 38(19): 2663-2665.
45.	Gómez Rueda V, Zuleta Tobón JJ. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae: a case-case-control study. Colomb Med (Cali), 2014, 45(2): 54-60.
46.	孫武銘, 周華, 馬文江, 等. 碳青霉烯耐藥肺炎克雷伯桿菌血流感染不同治療方案療效和安全性分析//2018 年（第四十屆）浙江省醫學會呼吸系病學術年會. 杭州: 浙江省科學技術協會, 2018: 26-32.
47.	Ni W, Yang D, Guan J, et al. In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother, 2021, 76(8): 2097-2105.
48.	Balkan II, Alkan M, Aygün G, et al. Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis, 2021, 40(10): 2161-2170.
49.	龍曉琴, 方麗. 耐碳青霉烯類肺炎克雷伯桿菌感染的研究進展. 疑難病雜志, 2021, 20(12): 1282-1286.
50.	Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis, 2020, 7: 2049936120912049.
51.	應穎秋, 張哲浩, 程吟楚, 等. 北京市 70 家醫院重癥監護病房碳青霉烯類抗菌藥物及替加環素應用的橫斷面研究. 中國醫院藥學雜志, 2019, 39(20): 2035-2039.
52.	Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore), 2016, 95(11): e3126.
53.	Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis, 2011, 11(11): 834-844.
54.	Dhandapani S, Sistla S, Gunalan A, et al. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E. coli and Klebsiella pneumoniae by checkerboard method. Indian J Med Microbiol, 2021, 39(1): 6-10.
55.	張莉, 胡淼, 陳媛, 等. 耐碳青霉烯類肺炎克雷伯桿菌肺部感染患者不同抗菌藥物聯合治療方案的療效與安全性分析. 藥學與臨床研究, 2022, 30(4): 315-318.
56.	van Duin D, Doi Y. Outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae: are we at the end of the road?. J Clin Microbiol, 2015, 53(10): 3116-3117.
57.	Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev, 2012, 25(4): 682-707.
58.	Shields RK, Clancy CJ, Press EG, et al. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother, 2016, 60(5): 3187-3192.
59.	Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother, 2017, 61(8): e00883-817.
60.	黃娟娟, 何鴿飛, 易愛純, 等. 磷霉素聯合依替米星治療耐碳青霉烯肺炎克雷伯菌重癥感染的療效. 中南藥學, 2017, 15(10): 1484-1487.
61.	史少明, 王明月, 梁文炎, 等. 頭孢他啶/阿維巴坦治療耐碳青霉烯類肺炎克雷伯桿菌感染的療效及影響因素分析. 醫學研究生學報, 2022, 35(11): 1190-1195.
62.	姜婷, 鄧飛, 惲波. 頭孢他啶-阿維巴坦治療耐碳青霉烯肺炎克雷伯菌肺部感染的療效. 江蘇醫藥, 2020, 46(12): 1286-1288.
63.	van Duin D, Lok J. J, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis, 2018, 66(2): 163-171.
64.	Findlay J, Poirel L, Juhas M, et al. KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae. Antimicrob Agents Chemother, 2021, 65(9): e0089021.
65.	Han X, Shi Q, Mao Y, et al. Emergence of ceftazidime/avibactam and tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae due to in-host microevolution. Front Cell Infect Microbiol, 2021, 11: 757470.

1. Soares de Moraes L, Gomes Magalhaes GL, Material Soncini JG, et al. High mortality from carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Microb Pathog, 2022, 167: 105519.
2. 康蓓佩, 付曉蕊, 賀文芳, 等. 耐碳青霉烯類的肺炎克雷伯菌的感染特點及耐藥基因分析. 國際檢驗醫學雜志, 2019, 40(24): 2991-2994, 2998.
3. 楊沙沙, 王喜仁, 韓杰, 等. 美國 CLSI 抗菌藥物敏感試驗操作標準(2010 年版)部分變更內容. 中國感染控制雜志, 2010, 9(4): 303-304.
4. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis, 2017, 215(Suppl_1): S28-S36.
5. Oteo J, Pérez-Vázquez M, Bautista V, et al. The spread of KPC-producing Enterobacteriaceae in Spain: WGS analysis of the emerging high-risk clones of Klebsiella pneumoniae ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. J Antimicrob Chemother, 2016, 71(12): 3392-3399.
6. Liao W, Liu Y, Zhang W. Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: a review over the last 10 years. J Glob Antimicrob Resist, 2020, 23: 174-180.
7. Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol, 2013, 4: 48.
8. 禹明均, 鄭小鵬, 李春江. 耐碳青霉烯類肺炎克雷伯菌耐藥機制的研究進展. 現代鹽化工, 2022, 49(3): 13-15.
9. 許曉娜, 王志盛, 張小倩, 等. 耐碳青霉烯類肺炎克雷伯菌耐藥機制的研究進展. 河南醫學研究, 2018, 27(17): 3125-3126.
10. Ho PL, Cheung YY, Wang Y, et al. Characterization of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from a healthcare region in Hong Kong. Eur J Clin Microbiol Infect Dis, 2016, 35(3): 379-385.
11. 王芬芳, 楊坤祥, 徐華. 新生兒醫院感染肺炎克雷伯菌的耐藥性分析. 國際檢驗醫學雜志, 2017, 38(1): 107-109.
12. 趙容陶, 娜木罕, 朝寶, 等. 新生兒肺炎克雷伯菌敗血癥的臨床特征及耐藥性分析. 中國婦幼健康研究, 2022, 33(6): 96-102.
13. 杜逸亭, 胡旭紅, 楊曉榮, 等. 新生兒肺炎克雷伯菌敗血癥臨床特點和藥敏分析. 四川醫學, 2017, 38(12): 1420-1423.
14. 2020 年全國細菌耐藥監測報告. 中國合理用藥探索, 2022, 19(11): 83.
15. 郝東俠, 王彥宏, 王旭東. 醫院獲得性耐碳青霉烯肺炎克雷伯桿菌感染的特點、危險因素分析及預后. 中國臨床醫生雜志, 2019, 47(5): 522-525.
16. Pellegrini JL, Aguirre C, Soto SM, et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from a pediatric hospital from Corrientes, Argentina. Rev Chilena Infectol, 2022, 39(2): 109-116.
17. Candevir Ulu A, Güven G?kmen T, Kibar F, et al. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae at a Turkish centre: is the increase of resistance a threat for Europe?. J Glob Antimicrob Resist, 2017, 11: 10-16.
18. Ghamari M, Beigverdi R, Jabalameli F, et al. Antimicrobial resistance pattern, virulence determinants and molecular analysis of carbapenem-resistant Klebsiella pneumoniae isolated from clinical samples in Iran. FEMS Microbiol Lett, 2022, 369(1): fnac100.
19. Chen IR, Huang PH, Wu PF, et al. Clinical characteristics and outcomes of 56 patients with pneumonia caused by carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist, 2021, 25: 326-330.
20. Lee YL, Ko WC, Hsueh PR. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents, 2022, 60(5/6): 106679.
21. Tesfa T, Mitiku H, Edae M, et al. Prevalence and incidence of carbapenem-resistant K. pneumoniae colonization: systematic review and meta-analysis. Syst Rev, 2022, 11(1): 240.
22. Ahmed El-Domany R, El-Banna T, Sonbol F, et al. Co-existence of NDM-1 and OXA-48 genes in carbapenem resistant Klebsiella pneumoniae clinical isolates in Kafrelsheikh, Egypt. Afr Health Sci, 2021, 21(2): 489-496.
23. Thapa S, Adhikari N, Shah AK, et al. Detection of NDM-1 and VIM genes in carbapenem-resistant Klebsiella pneumoniae isolates from a tertiary health-care center in Kathmandu, Nepal. Chemotherapy, 2021, 66(5/6): 199-209.
24. Berglund B, Hoang NTB, Lundberg L, et al. Clonal spread of carbapenem-resistant Klebsiella pneumoniae among patients at admission and discharge at a Vietnamese neonatal intensive care unit. Antimicrob Resist Infect Control, 2021, 10(1): 162.
25. Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis, 2014, 20(7): 1170-1175.
26. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob, 2017, 16(1): 18.
27. Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev, 2016, 80(3): 629-661.
28. Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol, 2018, 8: 4.
29. Gomez-Simmonds A, Uhlemann AC. Clinical implications of genomic adaptation and evolution of carbapenem-resistant Klebsiella pneumoniae. J Infect Dis, 2017, 215(Suppl_1): S18-S27.
30. Arato V, Raso MM, Gasperini G, et al. Prophylaxis and treatment against Klebsiella pneumoniae: current insights on this emerging anti-microbial resistant global threat. Int J Mol Sci, 2021, 22(8): 4042.
31. Han R, Niu M, Liu S, et al. The effect of siderophore virulence genes entB and ybtS on the virulence of carbapenem-resistant Klebsiella pneumoniae. Microb Pathog, 2022, 171: 105746.
32. 于新橋. 早產兒敗血癥臨床治療中碳青霉烯類和 β-內酰胺類藥物的使用與耐藥性分析. 檢驗醫學與臨床, 2017, 14(7): 1021-1024.
33. Ruiz J, Gordon M, Villarreal E, et al. Influence of antibiotic pressure on multi-drug resistant Klebsiella pneumoniae colonisation in critically ill patients. Antimicrob Resist Infect Control, 2019, 8: 38.
34. Li M, Yang S, Yao H, et al. Retrospective analysis of epidemiology, risk factors, and outcomes of health care-acquired carbapenem-resistant Klebsiella pneumoniae bacteremia in a Chinese tertiary hospital, 2010-2019. Infect Dis Ther, 2023, 12(2): 473-485.
35. Qian Y, Bi Y, Liu S, et al. Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review. Ann Palliat Med, 2021, 10(7): 7340-7350.
36. Liu P, Li X, Luo M, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis. Microb Drug Resist, 2018, 24(2): 190-198.
37. Yuan Y, Wang J, Yao Z, et al. Risk Factors for carbapenem-Resistant Klebsiella pneumoniae bloodstream infections and outcomes. Infect Drug Resist, 2020, 13: 207-215.
38. Lu J, Zhang A, Han L, et al. Clinical outcomes and risk factors for death following carbapenem-resistant Klebsiella pneumoniae infection in solid organ transplant recipients. Microbiol Spectr, 2023, 11(1): e0475522.
39. Manandhar S, Amatya P, Ansari I, et al. Risk factors for the development of neonatal sepsis in a neonatal intensive care unit of a tertiary care hospital of Nepal. BMC Infect Dis, 2021, 21(1): 546.
40. Akgul F, Bozkurt I, Sunbul M, et al. Risk factors and mortality in the carbapenem-resistant Klebsiella pneumoniae infection: case control study. Pathog Glob Health, 2016, 110(7/8): 321-325.
41. Qin X, Wu S, Hao M, et al. The colonization of carbapenem-resistant Klebsiella pneumoniae: epidemiology, resistance mechanisms, and risk factors in patients admitted to intensive care units in China. J Infect Dis, 2020, 221(Suppl 2): S206-S214.
42. Ding Y, Wang Y, Hsia Y, et al. Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. Ann Clin Microbiol Antimicrob, 2019, 18(1): 36.
43. 陳虹宇, 黃雙雙, 孫麗芳, 等. 兒童檢出耐碳青霉烯類肺炎克雷伯菌的影響因素分析. 檢驗醫學與臨床, 2021, 18(2): 168-171.
44. 方清永, 李迎麗, 邱景富. ICU 耐碳青霉烯類肺炎克雷伯菌醫院獲得性肺炎危險因素分析. 國際檢驗醫學雜志, 2017, 38(19): 2663-2665.
45. Gómez Rueda V, Zuleta Tobón JJ. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae: a case-case-control study. Colomb Med (Cali), 2014, 45(2): 54-60.
46. 孫武銘, 周華, 馬文江, 等. 碳青霉烯耐藥肺炎克雷伯桿菌血流感染不同治療方案療效和安全性分析//2018 年（第四十屆）浙江省醫學會呼吸系病學術年會. 杭州: 浙江省科學技術協會, 2018: 26-32.
47. Ni W, Yang D, Guan J, et al. In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother, 2021, 76(8): 2097-2105.
48. Balkan II, Alkan M, Aygün G, et al. Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis, 2021, 40(10): 2161-2170.
49. 龍曉琴, 方麗. 耐碳青霉烯類肺炎克雷伯桿菌感染的研究進展. 疑難病雜志, 2021, 20(12): 1282-1286.
50. Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis, 2020, 7: 2049936120912049.
51. 應穎秋, 張哲浩, 程吟楚, 等. 北京市 70 家醫院重癥監護病房碳青霉烯類抗菌藥物及替加環素應用的橫斷面研究. 中國醫院藥學雜志, 2019, 39(20): 2035-2039.
52. Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore), 2016, 95(11): e3126.
53. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis, 2011, 11(11): 834-844.
54. Dhandapani S, Sistla S, Gunalan A, et al. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E. coli and Klebsiella pneumoniae by checkerboard method. Indian J Med Microbiol, 2021, 39(1): 6-10.
55. 張莉, 胡淼, 陳媛, 等. 耐碳青霉烯類肺炎克雷伯桿菌肺部感染患者不同抗菌藥物聯合治療方案的療效與安全性分析. 藥學與臨床研究, 2022, 30(4): 315-318.
56. van Duin D, Doi Y. Outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae: are we at the end of the road?. J Clin Microbiol, 2015, 53(10): 3116-3117.
57. Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev, 2012, 25(4): 682-707.
58. Shields RK, Clancy CJ, Press EG, et al. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother, 2016, 60(5): 3187-3192.
59. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother, 2017, 61(8): e00883-817.
60. 黃娟娟, 何鴿飛, 易愛純, 等. 磷霉素聯合依替米星治療耐碳青霉烯肺炎克雷伯菌重癥感染的療效. 中南藥學, 2017, 15(10): 1484-1487.
61. 史少明, 王明月, 梁文炎, 等. 頭孢他啶/阿維巴坦治療耐碳青霉烯類肺炎克雷伯桿菌感染的療效及影響因素分析. 醫學研究生學報, 2022, 35(11): 1190-1195.
62. 姜婷, 鄧飛, 惲波. 頭孢他啶-阿維巴坦治療耐碳青霉烯肺炎克雷伯菌肺部感染的療效. 江蘇醫藥, 2020, 46(12): 1286-1288.
63. van Duin D, Lok J. J, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis, 2018, 66(2): 163-171.
64. Findlay J, Poirel L, Juhas M, et al. KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae. Antimicrob Agents Chemother, 2021, 65(9): e0089021.
65. Han X, Shi Q, Mao Y, et al. Emergence of ceftazidime/avibactam and tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae due to in-host microevolution. Front Cell Infect Microbiol, 2021, 11: 757470.

West China Medical Journal

Research progress on influencing factors of drug resistance of carbapenem-resistant Klebsiella pneumoniae

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content